一年前， Arm与高通展开了一场高风险的法律争执，随着这家英国芯片公司本周上市，这场争执正在 酝酿之中。 Arm正在起诉Nuvia，后者此前已经被高通收购。作为进军PC处理器市场的一部分，高通于2021年收购 了Nuvia。Arm希望高通要么支付更高的专利使用费，要么停止未经许可使用其专利技术。此案定于明 年年底开庭审理。 Arm备受期待的首次公开募股将成为2023年规模最大的一次上市活动，而这次IPO增加了该公司赢得或 达成有利和解的压力。Arm必须向投资者证明，他们已牢牢掌控了自己的知识产权，并有能力实现许可 收入的增长。但是，收购了Nuvia以加强产品供应的高通也面临着自己的挑战，因为智能手机的销量下 滑挤压了该公司的利润空间，而高通一直都是智能手机的主要芯片供应商。 以下是关于这场诉讼的重要信息，以及它对Arm上市活动的影响。 争端 去年8月，Arm在美国特拉华州提起诉讼，指控高通在未就新许可进行谈判的情况下，利用从Nuvia收购 的技术进行开发。高通公司提起反诉，声称自己没有任何违法行为，Arm不能要求其销毁利用Nuvia知 识产权构建的处理器芯片技术。 Research半导体分析师吉姆·麦格雷戈（ ...

Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of CNY 345,327.15 million, a year-on-year increase of 8.52% [2] - In Q3 2025, the company reported operating revenue of CNY 118,960.39 million, up 13.40% compared to the same period last year [2] - The net profit attributable to the parent company for the first three quarters was CNY 21,100.34 million, a decrease of 17.36% year-on-year [2] - In Q3 2025, the net profit attributable to the parent company was CNY 3,034.87 million, down 47.55% year-on-year [2] Impact of Legal Settlements - The significant decline in net profit was primarily due to a payment of USD 19 million (approximately CNY 136,095,100) related to a cross-licensing agreement with Roche [3][6] - After excluding the impact of the Roche settlement, the net profit for Q3 2025 would have been CNY 105,200,969.32, reflecting an 82% increase year-on-year [3] Patent Litigation and Settlements - Trividia Health Inc. (THI) faced a patent infringement lawsuit from Roche, which was settled in October 2025 [4][6] - The settlement included a cross-licensing agreement covering at least 39 U.S. patents, allowing THI to continue its operations without ongoing litigation [5][6] - The company is also involved in ongoing litigation with Abbott regarding its CGM products in Europe, with a temporary injunction granted against one of its products [7][8] Product Development and Market Strategy - The second-generation CGM product received EU CE MDR certification on July 2, 2025, allowing it to be sold in EU member states [9] - The company is assessing the market entry strategy for its second-generation CGM product in Europe to mitigate patent risks [10] - The user demographic for CGM products primarily includes type 2 diabetes patients, with a focus on those requiring regular blood glucose monitoring [14][15] Future Outlook - The company plans to appeal the temporary injunction related to Abbott's patents and is committed to continuing its FDA application process for the second-generation CGM product [12][13] - The overall business performance remains stable, with both traditional and CGM business segments showing double-digit growth [3]

Group 1 - The company has a subsidiary, Jiangsu Tairui Lanteng Material Technology Co., Ltd., which has obtained a patent for lithium sulfide materials and their preparation methods and applications [2] - The company is responding to investor inquiries regarding the research and development of lithium sulfide and the potential for technology licensing [2]

Core Viewpoint - Xinhua Medical (600587) has recently obtained a new utility model patent for a "sampling device," with the application number CN202422198530.3, authorized on July 22, 2025 [1] Group 1: Patent and Innovation - The newly authorized patent relates to a sampling device that includes an elastic pressing chamber connected to a sampling tube and a pressing mechanism [1] - In 2023, Xinhua Medical has received a total of 149 patent authorizations, which is a decrease of 4.49% compared to the same period last year [1] Group 2: Research and Development - In the 2024 annual report, Xinhua Medical invested 436 million yuan in research and development, reflecting a year-on-year decrease of 1.64% [1] Group 3: Company Activities - Xinhua Medical has made investments in 54 companies and participated in 10,268 bidding projects [1] - The company holds 207 trademark records, 4,334 patent records, and 360 copyright records [1]

Group 1 - The company Nuway CNC (688697) has recently obtained a utility model patent for a "brake locking mechanism," with the patent application number CN202421842341.9 and an authorization date of July 8, 2025 [1] - The patent describes a brake locking mechanism that includes a cylinder, piston, stator fixed plate, and brake pads, designed to reduce the swing angle of a five-axis cradle turntable during power outages or emergency stops, thereby lowering the overall cost of the locking mechanism [1] - In 2023, Nuway CNC has received 35 new patent authorizations, representing a 105.88% increase compared to the same period last year [1] Group 2 - The company has invested in one external enterprise and participated in 246 bidding projects [2] - Nuway CNC holds 21 trademark records, 388 patent records, and 15 copyright records, along with 44 administrative licenses [2] - In 2024, the company invested 112 million yuan in research and development, reflecting a year-on-year increase of 10.35% [1]